In osteoporosis, there is an imbalance between bone resorption and bone formation leading to bone loss and structural decay of the skeleton.

Currently available therapeutics affect bone resorption and bone formation in the same direction and either decrease (inhibitors of bone resorption) or increase (PTH peptides) bone remodeling.

New classes of therapeutics for osteoporosis with different mechanisms of action are in clinical development.

Inhibitors of Cathepsin K reduce bone resorption while preserving bone formation and increase bone mineral density at the spine and the hip continuously for at least 5 years of treatment.

Inhibitors of sclerostin increase bone formation while reducing bone resorption and impressively increase bone mineral density at the spine and the hip.